[Acute cholestatic hepatitis caused by simvastatine in a 67-year-old patient]

Stanisław Lata1, Barbara Chudy

  • 1II Odział Chorób Wewnetrznych i Ostrych Zatruć Szpital Wojewódzki im. Sw. Lukasza w Tamowie.

Przeglad Lekarski
|September 7, 2007
PubMed

Insights

Simvastatin, a common cholesterol-lowering drug, can cause toxic hepatocellular damage, leading to jaundice and itching. Regular patient checkups are crucial for early diagnosis and management of statin-induced liver injury.

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Toxicology

Background:

  • Statins are widely prescribed for hyperlipidemia.
  • Hepatotoxicity is a rare but serious side effect of statin therapy.
  • Early identification of drug-induced liver injury is critical.

Observation:

  • A case study details a patient experiencing toxic hepatocellular damage.
  • Key symptoms included jaundice and pruritus.
  • The adverse event was linked to Simvastatin (Cardin) use.

Findings:

  • Simvastatin can induce significant liver damage.
  • Jaundice and pruritus are indicative symptoms of this side effect.
  • Prompt medical history and patient monitoring are essential.

Implications:

  • Highlights the importance of thorough patient history in diagnosing drug-induced liver injury.
  • Emphasizes the need for vigilant monitoring of patients on statin therapy.
  • Informs clinical practice regarding potential Simvastatin toxicity and management strategies.

Related Concept Videos

Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...